Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Non-Current Assets: 2010-2024

Historic Non-Current Assets for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to $756.0 million.

  • Ani Pharmaceuticals' Non-Current Assets fell 7.35% to $709.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $709.8 million, marking a year-over-year decrease of 7.35%. This contributed to the annual value of $756.0 million for FY2024, which is 96.57% up from last year.
  • As of FY2024, Ani Pharmaceuticals' Non-Current Assets stood at $756.0 million, which was up 96.57% from $384.6 million recorded in FY2023.
  • Ani Pharmaceuticals' Non-Current Assets' 5-year high stood at $756.0 million during FY2024, with a 5-year trough of $290.9 million in FY2020.
  • Moreover, its 3-year median value for Non-Current Assets was $415.8 million (2022), whereas its average is $518.8 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first declined by 7.56% in 2022, then skyrocketed by 96.57% in 2024.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' Non-Current Assets stood at $290.9 million in 2020, then surged by 54.65% to $449.8 million in 2021, then declined by 7.56% to $415.8 million in 2022, then decreased by 7.51% to $384.6 million in 2023, then skyrocketed by 96.57% to $756.0 million in 2024.